[go: up one dir, main page]

PE20090233A1 - Combinacion de antagonistas del receptor de progesterona con un inhibidor de la aromatasa - Google Patents

Combinacion de antagonistas del receptor de progesterona con un inhibidor de la aromatasa

Info

Publication number
PE20090233A1
PE20090233A1 PE2008000688A PE2008000688A PE20090233A1 PE 20090233 A1 PE20090233 A1 PE 20090233A1 PE 2008000688 A PE2008000688 A PE 2008000688A PE 2008000688 A PE2008000688 A PE 2008000688A PE 20090233 A1 PE20090233 A1 PE 20090233A1
Authority
PE
Peru
Prior art keywords
combination
progesterone receptor
aromatase inhibitor
receptor antagonists
cancer
Prior art date
Application number
PE2008000688A
Other languages
English (en)
Inventor
Jens Hoffmann
Daniel Korr
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39872870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090233(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20090233A1 publication Critical patent/PE20090233A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UNA COMBINACION FARMACEUTICA QUE COMPRENDE UN ANTAGONISTA DEL RECEPTOR DE PROGESTERONA TAL COMO 11BETA-(4-ACETILFENIL)-17BETA-HIDROXI-17ALFA-(1,1,2,2,2-PENTAFLUOROETIL)-ESTRA-4,9-DIEN-3-ONA (ZK230211 O ZK-PRA) Y UN INHIBIDOR DE LA AROMATASA TAL COMO AMINOGLUTETIMIDA, FADROZOL, ANASTROZOL, LETROZOL, VOROZOL, FORMESTANO, EXEMESTANO Y ATAMESTANO, DONDE LA RELACION DE PESO ENTRE EL ANTAGONISTA DEL RECPETOR DE PROGESTERONA Y EL INHIBIDOR DE LA AROMATASA ES DE ENTRE 1:100 Y 100:1. DICHA COMBINACION ES UTIL EN EL TRATAMIENTO DE CANCER DE MAMA, ENFERMEDADES RELACIONADAS CON MUTACIONES DE LOS GENES SUPRESORES DE TUMORES, BRCA1 Y BRCA2, TALES COMO CANCER DE OVARIO, CANCER DE ENDOMETRIO, CANCER GASTRICO, ENTRE OTROS
PE2008000688A 2007-04-23 2008-04-22 Combinacion de antagonistas del receptor de progesterona con un inhibidor de la aromatasa PE20090233A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07090081 2007-04-23
US91437307P 2007-04-27 2007-04-27

Publications (1)

Publication Number Publication Date
PE20090233A1 true PE20090233A1 (es) 2009-04-08

Family

ID=39872870

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000688A PE20090233A1 (es) 2007-04-23 2008-04-22 Combinacion de antagonistas del receptor de progesterona con un inhibidor de la aromatasa

Country Status (11)

Country Link
US (1) US20080261929A1 (es)
EP (1) EP2136842A1 (es)
JP (1) JP2010524994A (es)
AR (1) AR066232A1 (es)
CA (1) CA2684806A1 (es)
CL (1) CL2008001150A1 (es)
PA (2) PA8777401A1 (es)
PE (1) PE20090233A1 (es)
TW (1) TW200902028A (es)
UY (1) UY31043A1 (es)
WO (1) WO2008128784A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9603856B2 (en) 2013-11-03 2017-03-28 Flamina Holding Ag Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells
TWI639430B (zh) * 2016-08-27 2018-11-01 中國醫藥大學 醫藥組合物用於製備治療胃癌藥物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476079B1 (en) * 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
EE05259B1 (et) * 2000-10-18 2010-02-15 Schering Aktiengesellschaft Antiprogestiinide kasutamine hormoons?ltuvate haiguste proflaktikaks ja raviks
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Also Published As

Publication number Publication date
JP2010524994A (ja) 2010-07-22
PA8777501A1 (es) 2008-11-19
UY31043A1 (es) 2008-11-28
EP2136842A1 (en) 2009-12-30
CL2008001150A1 (es) 2008-11-03
TW200902028A (en) 2009-01-16
US20080261929A1 (en) 2008-10-23
PA8777401A1 (es) 2008-11-19
CA2684806A1 (en) 2008-10-30
WO2008128784A1 (en) 2008-10-30
AR066232A1 (es) 2009-08-05

Similar Documents

Publication Publication Date Title
CL2015001508A1 (es) Compuestos derivados de bencimidazol, antagonistas de receptores ep4; composicion farmaceutica; combinacion farmaceutica; uso para tratar y/o prevenir enfermedades tales como endometriosis, hemorragias uterinas, dismenorrea, canceres de pulmon, de intestino, de mama, de prostata, entre otros.
CY1125358T1 (el) Θεραπεια συνδυασμου η οποια περιλαμβανει εναν mdm2 αναστολεα και εναν ή περισσοτερους επιπροσθετους φαρμακευτικως δραστικους παραγοντες για την αντιμετωπιση καρκινων
MX394676B (es) Métodos para tratar el cáncer.
CY1122651T1 (el) Μεθοδοι και συνθεσεις για προσδιορισμο της αντιστασης εναντι θεραπειας υποδοχεα ανδρογονου
MX393924B (es) Ligandos degradadores selectivos del receptor de andrógenos (sard) y métodos de uso de los mismos.
CL2011002691A1 (es) Compuestos derivados de heterociclos sustituidos, inhibidores pi3k y/u objetivo mamifero de rapamicina (mtor); composicion farmaceutica que los comprende; y su uso en el tratamiento de melanoma, algun tipo de cancer tales como ovario, cuello uterino, mama, colon, recto, endometrio, entre otros.
HRP20150437T1 (xx) Diarilhidantoinski spojevi kao antagonisti androgenog receptora za lijeäśenje raka
PH12019502692A1 (en) Anti-cancer combination therapy
CY1113665T1 (el) Θετικοι αλλοστερικοι ρυθμιστες του υποδοχεα μ1 με αρυλομεθυλο βενζοκιναζολινονη
SG10201907684PA (en) Androgen receptor modulator and uses thereof
MX2018011419A (es) Moduladores de receptores estrogénicos.
EA201991622A1 (ru) Комплексная терапия для лечения рака
CL2008001047A1 (es) Compuestos derivados de difenil-dihidro-imidazopiridinonas; inhibidores de mdm2-p53;composicion farmaceutica;y uso para preparar un medicamento destinado al tratamiento o control de tumores solidos,tales como:tumores de mama.de colon,de pulmon o de prostata.
MX2020006219A (es) Derivados de 1-piperidinocarbonilmetil)-2-oxopiperazina para tratar cancer.
Shoda et al. Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator
BR112014016635B8 (pt) composto, composição, e, uso de um composto
PE20171738A1 (es) Proceso para la preparacion de antagonistas del receptor androgeno e intermediarios de los mismos
MX364985B (es) Antagonistas de imidazolil progesterona.
EA202190146A1 (ru) Активаторы реакции на несложенные белки
EA202091804A1 (ru) Гетероциклил-замещенные оксадиазолопиридиновые производные для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat)
PE20090233A1 (es) Combinacion de antagonistas del receptor de progesterona con un inhibidor de la aromatasa
EA201590522A1 (ru) Способы введения рифаксимина для снижения веса и лечения ожирения
PH12013501176A1 (en) Novel 19-nor-steroids and their use for treating progesterone-dependent conditions
ATE548365T1 (de) 5-ht7-rezeptorantagonisten
EA201290534A1 (ru) Бициклические тиазолы в качестве аллостерических модуляторов mglur5 рецепторов

Legal Events

Date Code Title Description
FA Abandonment or withdrawal